Skip to main content
Charles Leath III, MD, Obstetrics & Gynecology, Birmingham, AL, University of Alabama Hospital

CharlesAlexanderLeathIIIMD

Obstetrics & Gynecology Birmingham, AL

Gynecologic Oncology

Professor, Obstetrics & Gynecology, U of AL Sch of Med

Overview of Dr. Leath

Director, Division of Gynecologic Oncology

Ellen Gregg Shook Culverhouse Endowed Chair in Gynecologic Oncology

Professor (Tenured)

Education & Training

  • University of Alabama At Birmingham School of Public Health
    University of Alabama At Birmingham School of Public HealthMSPH, Clinical and Translational Sciences, 2012 - 2014
  • University of Alabama Hospital
    University of Alabama HospitalFellowship, Gynecologic Oncology, 2002 - 2005
  • University of Alabama Hospital
    University of Alabama HospitalResidency, Obstetrics and Gynecology, 1998 - 2002
  • Medical University of South Carolina College of Medicine
    Medical University of South Carolina College of MedicineClass of 1998
  • The Citadel, The Military College of South Carolina
    The Citadel, The Military College of South CarolinaBS, Biological Sciences, Magna Cum Laude, 1990 - 1994
  • University of South Carolina
    University of South CarolinaNo degree, 1992 - 1993

Certifications & Licensure

  • MS State Medical License
    MS State Medical License 2017 - 2023
  • TX State Medical License
    TX State Medical License 2006 - 2022
  • AL State Medical License
    AL State Medical License 1999 - 2022
  • SD State Medical License
    SD State Medical License Active through 2023
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

  • J. Bay Jacobs Travel Award American Gynecology and Obstetrical Society University of Alabama at Birmingham, 2016
  • First place poster presentation CaRES (Cancer Research Experience for Students) Division 18th Annual UAB Comprehensive Cancer Center Retreat, 2016
  • Top Ten Percent Reviewer, Gynecologic Oncology University of Alabama at Birmingham, 2015, 2017
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GO...  
    Miller C, Chappell N, Sledge C, Leath CA III, Phippen N, Havrilesky L, Barnett JC, Gynecol Oncol, 1/1/2017
  • Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – a multi-institutional cohort  
    Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM, Gunderson CC, Moore KN, Erickson BK, Leath CA III, Diaz ES, Cohen J, Walsh C, Gynecol Oncol, 1/1/2017
  • A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF ...  
    Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Thigpen JT, Lieberman R, Zuna RE, Leath CA III, Spirtos NM, Byron J, Thaker PH, Lele S, Albe..., Gynecol Oncol, 1/1/2017
  • Join now to see all

Abstracts/Posters

  • The cost-effectiveness of salpingectomy versus standard tubal ligation at the time of cesarean delivery
    Subramaniam A, Blanchard CT, Erickson BK, Szychowski J, Leath CA III, Biggio J, Huh WK, 38th Annual Meeting of Society of Maternal Fetal Medicine, Dallas, Texas, 1/1/2018
  • Impact of enhanced recovery after surgery (ERAS) protocol on the gastrointestinal tract in gynecologic oncology patients undergoing laparotomy
    Boitano T, Smith HJ, Rushton T, Johnston MC, Leath CA III, Straughn JM Jr, 23rd Winter meeting of the Society of Gynecologic Oncology, Aspen, Colorado, 1/1/2018
  • Analysis of clinical cancer gene panels by next generation sequencing in tumor and circulating cell-free DNA samples in recurrent ovarian cancer patients
    Londono AI, Farrukh N, Smith MK, Tawfik C, Alvarez RD, Huh WK, Bevis KS, Leath CA, Straughn JM, Yang SH, Harada S, Kim KH, Arend RC, 2017 AACR Precision Medicine Series, San Diego, CA, 1/1/2017
  • Join now to see all

Lectures

  • A randomized controlled trial of salpingectomy versus standard tubal ligation at the time of cesarean delivery 
    Dallas, Texas - 1/1/2018
  • A prospective phase II trial of the listeria-based human papillomavirus immunotherapy axalimogene filolisbac in second- and third-line metastatic cervical cancer: An N... 
    Washington, DC - 1/1/2017
  • Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma 
    Washington, DC - 1/1/2017
  • Join now to see all

Other

Press Mentions

  • The HPV Vaccine Is Now Approved for Adults 27 Through 45
    The HPV Vaccine Is Now Approved for Adults 27 Through 45October 9th, 2018
  • FDA Approves Use of HPV Vaccine for Adults 27 to 45
    FDA Approves Use of HPV Vaccine for Adults 27 to 45October 6th, 2018
  • HPV Vaccine Now FDA-Approved for Adults up to 45
    HPV Vaccine Now FDA-Approved for Adults up to 45October 8th, 2018

Grant Support

  • NCTN Deep South Research ConsortiumNIHPresent

Committees

  • Chair, GOG/NRG Oncology Cervical Cancer Committee 2018 - Present
  • Member, GOG/NRG Oncology Cervical Cancer Committee 2006 - Present

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna HMO
    BCBS Blue Card PPO
    BCBS California CaliforniaCare HMO
    Blue Shield California HMO
    Blue Shield California PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Health PPO
    Great West PPO
    Health Net California Large Group PPO
    Health Net HMO - Employer Group
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PHCS PPO - Kaiser
    Multiplan PPO
    Pacificare HMO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment